Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Blue-light damage is well-established risk in pseudophakia
Like most ophthalmologists, I knew little about the significant body of work in the peer-review literature documenting the harmful effects of visible blue-wavelength light on the retina. Because an effective solution to the problem seems to be on the way, the time has come for us to begin to recognize the implications of blue-light exposure in pseudophakic patients.
Related Videos
Related Content
